These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29633561)

  • 1. Approaches for simplified HCV diagnostic algorithms.
    Fourati S; Feld JJ; Chevaliez S; Luhmann N
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25058. PubMed ID: 29633561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for the improvement of HCV testing and diagnosis.
    Chevaliez S
    Expert Rev Anti Infect Ther; 2019 May; 17(5):341-347. PubMed ID: 30950298
    [No Abstract]   [Full Text] [Related]  

  • 3. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying cost-effective screening algorithms for active hepatitis C virus infections in a high prevalence setting.
    Jülicher P; Galli C
    J Med Econ; 2018 Jan; 21(1):1-10. PubMed ID: 28881157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplification of hepatitis C testing: a time to act.
    Poljak M
    Acta Dermatovenerol Alp Pannonica Adriat; 2020 Sep; 29(3):129-132. PubMed ID: 32975299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-care testing for HCV infection: recent advances and implications for alternative screening.
    Parisi MR; Soldini L; Vidoni G; Mabellini C; Belloni T; Brignolo L; Negri S; Schlusnus K; Dorigatti F; Lazzarin A
    New Microbiol; 2014 Oct; 37(4):449-57. PubMed ID: 25387283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.
    Grebely J; Applegate TL; Cunningham P; Feld JJ
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1109-1115. PubMed ID: 29088981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises.
    Shahid I; Alzahrani AR; Al-Ghamdi SS; Alanazi IM; Rehman S; Hassan S
    Diagnostics (Basel); 2021 Jul; 11(7):. PubMed ID: 34359335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: Analysis of key populations in Barcelona, Spain.
    Saludes V; Folch C; Morales-Carmona A; Ferrer L; Fernàndez-López L; Muñoz R; Jiménez M; Loureiro E; Fernández-Dávila P; Bascuñana E; Casabona J; Martró E
    J Viral Hepat; 2018 Mar; 25(3):236-244. PubMed ID: 29053912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in people who use injecting drugs in Senegal.
    Duchesne L; Hejblum G; Toure Kane NC; Njouom R; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
    Int J Drug Policy; 2020 Jan; 75():102613. PubMed ID: 31786434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.
    Kania D; Bekalé AM; Nagot N; Mondain AM; Ottomani L; Meda N; Traoré M; Ouédraogo JB; Ducos J; Van de Perre P; Tuaillon E
    Clin Microbiol Infect; 2013 Dec; 19(12):E533-41. PubMed ID: 23902574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time matters: Point of care screening and streamlined linkage to care dramatically improves hepatitis C treatment uptake in prisoners in England.
    Mohamed Z; Al-Kurdi D; Nelson M; Shimakawa Y; Selvapatt N; Lacey J; Thursz MR; Lemoine M; Brown AS
    Int J Drug Policy; 2020 Jan; 75():102608. PubMed ID: 31759307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination.
    Boeke CE; Adesigbin C; Agwuocha C; Anartati A; Aung HT; Aung KS; Grover GS; Ngo D; Okamoto E; Ngwije A; Nsanzimana S; Sindhwani S; Singh G; Sun LP; Kinh NV; Waworuntu W; McClure C
    BMJ Glob Health; 2020 Dec; 5(12):. PubMed ID: 33328200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa.
    Duchesne L; Hejblum G; Njouom R; Touré Kane C; Toni TD; Moh R; Sylla B; Rouveau N; Attia A; Lacombe K
    PLoS One; 2020; 15(8):e0238035. PubMed ID: 32833976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
    Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.